Asset Details
Do you wish to reserve the book?
EP1029 A preliminary study of genetic susceptibility and treatment related gene profiling in chinese ovarian cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
EP1029 A preliminary study of genetic susceptibility and treatment related gene profiling in chinese ovarian cancer patients
Do you wish to request the book?
EP1029 A preliminary study of genetic susceptibility and treatment related gene profiling in chinese ovarian cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
EP1029 A preliminary study of genetic susceptibility and treatment related gene profiling in chinese ovarian cancer patients
2019
Overview
Introduction/BackgroundThe purpose of our study was to presentgenetic susceptibility and treatment related gene profiling in Chinese ovarian cancer patients.MethodologyWe have applied next-generation sequencing in consecutive patients who underwent primary surgery for ovarian cancer since 2016 at our institution. 241 patients have been enrolled for blood tests so far. Paired tumor samples from 62 patients have been tested for somatic deleterious mutations.ResultsThe median (range) age of patients was 54 (35–83) years old. 27.4% (66/241) patients had germline deleterious mutations. The most frequently reported genes were as follows: 29 (12.8%) BRCA1 mutations, 19 (7.9%) BRCA2 mutations, 6 (2.5%) RAD51C mutations, and 6 (2.5%) RAD51D mutations. Other mutated genes investigated included BRIP1 (2), CHEK2 (2), RAD50 (2), MRE11A (2), PMS1 (1) and MLH1 (1). 4 patients had dual gene mutation, that is BRCA1/PMS1, BRCA1/RAD50, BRCA2/BRIP1, and BRCA2/RAD51D. For the paired tumor samples, 19 (30.6%) deleterious TP53 mutations were identified, 4 patients had somatic BRCA1 mutations and 1 patient had somatic BRCA2 mutation.ConclusionOur results suggest a comprehensive profiling for Chinese ovarian cancer patients. Somatic genetic test could help better stratify patients for individualized treatment.DisclosureNothing to disclose.
Publisher
Elsevier Inc,Elsevier Limited
Subject
